Mr. Mahoney stated that the medical device industry is valuable to the U.S. economy, and the tax has resulted in a reduction of jobs, as well as venture capital investment. Boston Scientific, he noted, pays about $75 million a year in tax.
“At Boston Scientific, we are paying the tax, but clearly it’s something we’d like to see repealed as part of a broader package,” he said, according to the report.
Additionally, Mr. Mahoney also discussed the company’s new Watchman device, which aims to help patients who are indicated for atrial fibrillation to help reduce the impact of stroke. The device recently received FDA approval and it will be a key product in the company’s portfolio, according to the report.
More articles on GI/endoscopy:
AGA: Asymptomatic pancreatic cysts do not require constant surveillance
Retroflexion vs. forward view in right colon ADR: 7 things to know
18 statistics on gastroenterologist habits & burnout
